Relmada Therapeutics Inc. Watch

from 8-K 3 pages Retention Compensation Agreement 1. Retention Compensation the Company Agrees to Pay the Employee Retention Compensation Totaling $1,500,000 Usd, Subject to the Terms and Conditions Outlined in This Agreement (The “Retention Compensation”). 2. Payment Schedule

from 8-K 3 pages Retention Compensation Agreement This Retention Compensation Agreement (The “Agreement”) Is Made and Entered Into as of August 27, 2024 by and Between Charles Ence (“Employee”) and Relmada Therapeutics, Inc. (“Company”). 1. Retention Compensation the Company Agrees to Pay the Employee Retention Compensation Totaling $2,000,000 Usd, Subject to the Terms and Conditions Outlined in This Agreement (The “Retention Compensation”). 2. Payment Schedule

from 8-K 3 pages Retention Compensation Agreement This Retention Compensation Agreement (The “Agreement”) Is Made and Entered Into as of August 27, 2024 by and Between Maged Shenouda (“Employee”) and Relmada Therapeutics, Inc. (“Company”). 1. Retention Compensation the Company Agrees to Pay the Employee Retention Compensation Totaling $2,000,000 Usd, Subject to the Terms and Conditions Outlined in This Agreement (The “Retention Compensation”). 2. Payment Schedule

from 8-K 3 pages Retention Compensation Agreement This Retention Compensation Agreement (The “Agreement”) Is Made and Entered Into as of August 27, 2024 by and Between Sergio Traversa (“Employee”) and Relmada Therapeutics, Inc. (“Company”). 1. Retention Compensation the Company Agrees to Pay the Employee Retention Compensation Totaling $4,200,000 Usd, Subject to the Terms and Conditions Outlined in This Agreement (The “Retention Compensation”). 2. Payment Schedule

from 8-K 10 pages On Behalf of Relmada Therapeutics, Inc: (The “Company”), I Am Pleased to Offer You the Position of Chief Accounting and Compliance Officer. Speaking for Myself, as Well as the Other Members of the Board of Directors, We Are All Impressed With Your Credentials and Look Forward to Your Future Success in This Position. the Terms of Your Employment Are Set Herein (“Employment Letter”). 1. Position. the Terms of Your Position With the Company Are as Set Forth Below

from 8-K 10 pages On Behalf of Relmada Therapeutics, Inc: (The “Company”), I Am Pleased to Offer You the Position of Chief Financial Officer. Speaking for Myself, as Well as the Other Members of the Board of Directors, We Are All Impressed With Your Credentials and Look Forward to Your Future Success in This Position. the Terms of Your Employment Are Set Herein (“Employment Letter”). 1. Position. the Terms of Your Position With the Company Are as Set Forth Below

from 8-K 10 pages (B) You Agree to Devote Your Best Efforts and Substantially All of Your Business Time to Advance the Interests of the Company and to Discharge Adequately Your Duties Hereunder. You May Hold Up to Two Board Seats on For-Profit and Not-For-Profit Boards That Do Not Represent a Conflict With the Company and Subject to Board Approval After Review of the Time Commitment Involved. 2. Effective Date. the Effective Date of This Agreement Shall Be January 1, 2025 (The “Effective Date”). 3. Proof of Right to Work. for Purposes of Federal Immigration Law, You Will Be Required to Provide to the Company Documentary Evidence of Your Identity and Eligibility for Employment in the United States. 4. Compensation

from 8-K 10 pages Paul Kelly 122 Sevilla Avenue Ph 14, Coral Gables, Fl 33134 Dear Mr. Kelly

from 8-K 24 pages Relmada Therapeutics, Inc. 2021 Equity Incentive Plan

from 8-K 7 pages Advisory Agreement

from 8-K 2 pages Amendment No. 2 to License Agreement

from 8-K 6 pages September 21, 2022 Relmada Therapeutics, Inc. 2222 Ponce De Leon, Floor 3 Coral Gables, Fl 33134 Re: Section 3(a)(9) Exchange Agreement Ladies and Gentlemen

from 8-K 22 pages Relmada Therapeutics, Inc. 2021 Equity Incentive Plan

from 10-Q 28 pages License Agreement

from 8-K 24 pages Relmada Therapeutics, Inc. 2021 Equity Incentive Plan

from 10-K 24 pages Relmada Therapeutics, Inc. 2021 Equity Incentive Plan

from 10-Q 38 pages Relmada Therapeutics, Inc., a Nevada Corporation (The “Company”), Proposes, Subject to the Terms and Conditions Stated Herein, to Issue and Sell From Time to Time Through Jefferies LLC, as Sales Agent and/or Principal (The “Agent”), Shares of the Company’s Common Stock, Par Value $0.001 Per Share (The “Common Shares”), on the Terms Set Forth in This Agreement (This “Agreement”). Section 1. Definitions (A) Certain Definitions. for Purposes of This Agreement, Capitalized Terms Used Herein and Not Otherwise Defined Shall Have the Following Respective Meanings

from 10-Q 8 pages Separation and Settlement Agreement by and Between Relmada Therapeutics, Inc. and Ottavio Vitolo, M.D

from 8-K 6 pages 1. Position. the Terms of Your New Position With the Company Are as Set Forth Below

from 8-K 1 page Amendment No. 5 to Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan, as Amended